Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Catabasis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Catabasis Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Catabasis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Catabasis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Catabasis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Catabasis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Catabasis Pharma Raises USD12.41 Million in Venture Financing 11
Catabasis Pharma Raises US$32.4 Million In Series B Financing 12
Partnerships 14
Catabasis Pharma Enters into Agreement with Sarepta Therapeutics 14
Catabasis Pharma Enters into Co-Development Agreement with Muscular Dystrophy Association 15
Catabasis Pharma Enters into Agreement with Actigraph 16
Equity Offering 17
Catabasis Pharma Raises USD42 Million in IPO of Shares 17
Catabasis Pharma Plans to Raise up to USD10 Million in Public Offering of Shares 18
Catabasis Pharma Raises USD4.3 Million in Public Offering of Shares 19
Catabasis Pharma Raises USD11.5 Million in Public Offering of Shares 20
Catabasis Pharma Raises USD69 Million in IPO 22
Catabasis Pharmaceuticals Inc – Key Competitors 23
Catabasis Pharmaceuticals Inc – Key Employees 24
Catabasis Pharmaceuticals Inc – Locations And Subsidiaries 25
Head Office 25
Recent Developments 26
Financial Announcements 26
Aug 09, 2018: Catabasis Pharmaceuticals reports second quarter 2018 financial results and reviews business progress 26
May 10, 2018: Catabasis Pharmaceuticals Reports First Quarter 2018 Financial Results and Reviews Business Progress 28
Mar 15, 2018: Catabasis Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Reviews Business Progress 29
Nov 09, 2017: Catabasis Pharmaceuticals Reports Third Quarter 2017 Financial Results 31
Aug 10, 2017: Catabasis Pharmaceuticals Reports Second Quarter 2017 Financial Results and Reviews Business Progress 33
May 11, 2017: Catabasis Pharmaceuticals Reports First Quarter 2017 Financial Results and Reviews Business Progress 35
Mar 16, 2017: Catabasis Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Recent Corporate Highlights 37
Corporate Communications 39
Feb 17, 2017: Catabasis Pharmaceuticals Announces Promotion of Ted Hibben to Chief Business Officer 39
Product News 40
09/28/2017: Catabasis Pharmaceuticals to Present Results from Joint Research Collaboration with Sarepta Therapeutics at the 22nd International Congress of the World Muscle Society 40
04/25/2017: Catabasis Pharmaceuticals Announces Favorable Results for Functional Assessments in the MoveDMD Trial for Edasalonexent in Duchenne Muscular Dystrophy at the American Academy of Neurology 69th Annual Meeting 41
01/31/2017: Catabasis Pharmaceuticals Announces Top-Line Results for Part B of the MoveDMD Trial for Edasalonexent (CAT-1004) in Duchenne Muscular Dystrophy 43
Clinical Trials 45
Oct 03, 2018: Catabasis Pharmaceuticals presents data supporting MRI T2 as a potential marker of clinical outcome in duchenne muscular dystrophy at the World Muscle Society Congress 45
Sep 27, 2018: Catabasis Pharmaceuticals begins Phase lll DMD trial of edasalonexent 47
Sep 19, 2018: Catabasis Pharmaceuticals to present new Edasalonexent clinical results and phase 3 trial design in duchenne muscular dystrophy at the World Muscle Society Congress 48
Jul 09, 2018: Catabasis to initiate POLARIS DMD trial of edasalonexent 49
Jun 25, 2018: Catabasis Pharmaceuticals Presents New Edasalonexent Clinical Biomarker Data Showing NF-kB Inhibition and Target Engagement in the MoveDMD Trial 50
Jun 18, 2018: Catabasis Pharmaceuticals to Present at Upcoming Scientific and Advocacy Conferences 51
Apr 25, 2018: Catabasis Pharmaceuticals Presents New Edasalonexent Data Showing Significantly Slowed Duchenne Muscular Dystrophy Disease Progression As Measured By MRI Through One Year Of Treatment 52
Apr 18, 2018: Catabasis Pharmaceuticals to Present Results from the MoveDMD Trial of Edasalonexent in Duchenne Muscular Dystrophy at the American Academy of Neurology 70th Annual Meeting 54
Apr 17, 2018: Catabasis Pharmaceuticals Aligns Resources to Focus on Lead Program Edasalonexent for the Treatment of Duchenne Muscular Dystrophy 55
Feb 13, 2018: Catabasis Pharmaceuticals Reports Edasalonexent Preserved Muscle Function and Substantially Slowed Duchenne Muscular Dystrophy Disease Progression Through More Than One Year of Treatment 56
Oct 04, 2017: Catabasis Pharmaceuticals Reports Positive Results From Open-Label Extension Of Phase 2 MoveDMD Trial Evaluating Edasalonexent In Duchenne Muscular Dystrophy And Plans To Initiate Phase 3 Clinical Trial In First Half 2018 58
Sep 14, 2017: Catabasis Pharmaceuticals to Present Results from the Open-Label Extension of the MoveDMD Phase 2 Trial of Edasalonexent in Duchenne Muscular Dystrophy in a Late Breaking Session of the World Muscle Society 60
Jun 23, 2017: Catabasis Pharmaceuticals to Present Results from the MoveDMD Trial of Edasalonexent at the 2017 PPMD Annual Connect Conference 61
Jan 19, 2017: Catabasis Pharmaceuticals Phase 1 Data on Edasalonexent (CAT-1004), a Potential Disease-Modifying Therapy Being Developed for Duchenne Muscular Dystrophy, Published in the Journal of Clinical Pharmacology 62
Jan 04, 2017: Positive Preclinical Research on the Edasalonexent (CAT-1004) Program, a Potential Disease-Modifying Therapy for Duchenne Muscular Dystrophy, Published in JCI Insight 63
Appendix 64
Methodology 64
About GlobalData 64
Contact Us 64
Disclaimer 64
Catabasis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Catabasis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Catabasis Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Catabasis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Catabasis Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Catabasis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Catabasis Pharma Raises USD12.41 Million in Venture Financing 11
Catabasis Pharma Raises US$32.4 Million In Series B Financing 12
Catabasis Pharma Enters into Agreement with Sarepta Therapeutics 14
Catabasis Pharma Enters into Co-Development Agreement with Muscular Dystrophy Association 15
Catabasis Pharma Enters into Agreement with Actigraph 16
Catabasis Pharma Raises USD42 Million in IPO of Shares 17
Catabasis Pharma Plans to Raise up to USD10 Million in Public Offering of Shares 18
Catabasis Pharma Raises USD4.3 Million in Public Offering of Shares 19
Catabasis Pharma Raises USD11.5 Million in Public Offering of Shares 20
Catabasis Pharma Raises USD69 Million in IPO 22
Catabasis Pharmaceuticals Inc, Key Competitors 23
Catabasis Pharmaceuticals Inc, Key Employees 24
List of Figures
Catabasis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Catabasis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Catabasis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Catabasis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Catabasis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Catabasis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Catabasis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Catabasis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9